Kulikov A.Y., Novikov I.V. 4926

Pharmacoeconomic study of canagliflozin (invocana) therapy as a part of combined therapy for patients with type 2 diabetes mellitus

Study purpose: to determine whether canagliflozin is a pharmacoeconomically justified option to be included into therapy for patients with insufficient glycemic control and treated with metformin either as monotherapy administered in the maximum tolerated dose or as a part of a combined therapy with sulfonylurea derivatives taking into account the conditions existing in the Russian Federation.
Скорее всего ваш браузер не поддерживает PDF и Adobe Reader, нажмите здесь, чтобы просмотреть PDF